International Clinical Trials Day 2026, a year in review: Access to Trials
CLINICAL TRIALS IN REGIONAL, RURAL AND REMOTE AUSTRALIA
With
Amanda Koegelenberg,
CEO, Novatrials
INTERNATIONAL CLINICAL TRIALS DAY SERIES SEGMENT
Filmed in Newcastle, NSW | May 2026
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leading up to 20th May with interviews captured across Australia. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials. The first segment is an example of how in-person clinical trial access has improved for regional, rural and remote communities.
Novatrials is helping transform access to clinical trials for people living in regional, rural and remote communities across the Hunter New England region and beyond. Based in Newcastle, New South Wales, the organisation was founded with a vision to bring innovative medical treatments closer to communities that have traditionally faced significant travel barriers to access state-of-the-art healthcare.
With the first purpose-built Phase 1 clinical trial facility outside of an Australian capital city, Novatrials is expanding opportunities for participants across Newcastle, the wider Hunter region and regional New South Wales to take part in world-class research closer to home. By conducting Phase 1 through to Phase 4 studies across a range of therapeutic areas, the organisation is helping bridge the gap between laboratory innovation and real-world patient care.
According to CEO Amanda Koegelenberg, the investment in the facility illustrates Novatrials’ commitment to ensuring people in regional and remote areas no longer need to travel vast distances to participate in clinical trials, while also bringing more research investment, innovation and healthcare opportunities into the Hunter New England region.
The segment highlights how Novatrials is working collaboratively with partners including the University of Newcastle, Hunter Medical Research Institute and Hunter New England Local Health District to strengthen the region’s research ecosystem and improve access to emerging treatments for local communities.
Source: Adapted from transcript using AI
You Might also like
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Clinical Trials Funding and Operating Models Government Medical Research New Content Op-Ed Translation, Market Access, Reimbursement
Op-Ed: CGT and proposed RDTI changes creating uncertainty in life sciences
Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas.
-
Inaugural report into Australasian Paramedicine Workforce Survey report to aid workforce planning
In a milestone for paramedicine, the Australasian College of Paramedicine earlier this year released the first report of a landmark three-year study identifying and exploring trends that affect the Australasian paramedicine workforce.
The inaugural Australasian Paramedicine Workforce Survey report 2023-24 explores the demographic, career trajectory, work motivations and conditions for those working in clinical, management and educational capacities within the paramedicine workforce of Australia and Aotearoa New Zealand.